I will be "over redundant" here by saying we are i
Post# of 155139
(Total Views: 483)
Posted On: 05/21/2025 5:27:55 PM
Re: KenChowder #153378
I will be "over redundant" here by saying we are in a "very unique" situation, not a normal situation in that Leronlimab is not single indication drug. How much the company is worth is not relevant IMHO, how much Leronlimab is worth is relevant. If this were a one indication drug in a small company, non of us would be here.
But this is different. Questions arise like how many on Leronlimab for HIV died of Covid, or had other cancer tumors? "What would happen in co-therapy with LL, drugs each having a different mechanism of action?" is a typical conversation here.
Any company in a BO would know know this, all of us know this and we aren't working for a Big Pharma firm. (maybe some are) Those in charge of buying other companies drugs know this, that's their job.
But this is different. Questions arise like how many on Leronlimab for HIV died of Covid, or had other cancer tumors? "What would happen in co-therapy with LL, drugs each having a different mechanism of action?" is a typical conversation here.
Any company in a BO would know know this, all of us know this and we aren't working for a Big Pharma firm. (maybe some are) Those in charge of buying other companies drugs know this, that's their job.
(9)
(0)